History and Background

BioUETIKON Ltd is the new name for a company that was established in 1998 at Dublin City University to facilitate the provision of contract production and development services to the biopharmaceutical industry. The company's services include GMP-compliant animal cell culture and downstream processing activities for development or manufacture of active pharmaceutical ingredients (APIs). Products can be for clinical trial or market supply and typical application areas are recombinant proteins, cell therapy products and monoclonal antibodies. BioUETIKON also provides services for scale-up of mammalian/insect cell culture, purification processes and joint R&D services.

In September 2006 CU Chemie Uetikon , a division of the Swiss based CPH Chemie and Papier Holdings AG, acquired an 80% share in the service orientated bioprocessing company Archport Ltd. In 2007, the company was renamed BioUETIKON Limited. CU Chemie Uetikon GmbH enjoys a proud history of production partnership to the pharmaceutical industry. This acquisition has broadened the company's technology base enabling it to become a complete systems partner of the global pharmaceutical sector.

CU Chemie Uetikon GmbH based in Lahr, Germany, has a proud reputation for providing the highest standards of quality, reliability, confidentiality and financial strength while supporting its customers with capacity ranging from grams through multi-kilo to multi-ton scale. Its main business activities include Custom Synthesis, production of Generic API's and Orphan Drugs, and delivery of various key intermediates and specialty chemicals. A new multi-purpose state-of-the-art GMP plant guarantees the highest level of quality and GMP-compliance. All operations are successfully FDA inspected.

With the strong financial backing of the Swiss CPH Chemie + Papier Holding organisation, customers can expect highest performance, continuous investments in capacities and long standing support of their projects.

BioUETIKON is especially aware of the challenges facing many companies attempting to deal with the new ‘Good Clinical Practices’ (GCP) regulations which are being introduced into Europe and we are well equipped to help firms successfully meet those challenges.

BioUETIKON provides GMP consultancy and trainers. We can organise lectures, workshops, hands on training and site visits. Our team has an impressive collective knowledge on many aspects of the biopharmaceutical industry, including process optimisation, validation and regulatory issues.

BioUETIKON has helped companies like Diosynth b.v. and GeneMedix Plc to meet their production and development requirements in a timely, flexible manner. BioUETIKON sees its clients as long term partners - seeking to meet not just the needs of the present but also future challenges.